The present invention generally provides methods and compositions for the treatment of Parkinson's disease and depression and/or anxiety. The invention relates to recombinant microorganisms, particularly gut-colonizing probiotics, modified to produce L-DOPA.

The disclosed subject matter provides for genetically modified cells, e.g., fungal cells, that autonomously generates and/or secretes one or more therapeutic molecules, e.g., therapeutic peptides, therapeutic proteins or small therapeutic molecules, in situ. In certain embodiments, the present disclosure provides genetically-engineered fungal cells that generate and secrete tetracycline and analogues thereof.

Certain embodiments provide a method for preparing a biochemical product (e.g., phenol, catechol, or muconic acid, or a salt thereof). For example, such methods include contacting a recombinant host having two or more recombinant pathways with a fermentable carbon source and growing the recombinant cell for a time sufficient to synthesize the product. In certain embodiments, each recombinant pathway: 1) is capable of producing the same final biochemical product; 2) comprises at least one gene encoding a polypeptide; 3) is derived from a different endogenous metabolite as its immediate precursor; and 4) converges to the same final product or the same intermediate metabolite.

The present invention relates a plant which may comprise a modified F5H gene homolog, wherein said gene homolog may comprise a modification as compared to its corresponding wild type F5H gene homolog, wherein the presence of the modified F5H gene homolog in the plant leads to a reduction of wound-induced surface discoloration in comparison to a plant not comprising the modified F5H gene homolog. The invention also relates to a modified F5H gene homolog that leads to the reduced wound-induced surface discoloration. The invention further relates to use of the gene in breeding and producing plants that show reduced wound-induced surface discoloration.

The present application relates to the technical field of genetic engineering, and provides a monooxygenase mutant, a preparation method and application thereof. The monooxygenase mutant has any one of the amino acid sequences shown in (I) and (II): (I) an amino acid sequence having at least 80% identity with the amino acid sequence shown in SEQ ID NO. 1; and (II) an amino acid sequence obtained by modifying, substituting, deleting, or adding one or several amino acids to the amino acids at 23 to 508 positions of the amino acid sequence shown in SEQ ID NO. 1, the substituting referring to a substitution of 1 to 34 amino acids, wherein the mutant has the activity of monooxygenase.

The present invention relates to a selective process for preparing sulfones from sulfides by enzymatic catalysis, and to a composition comprising a symmetrical sulfide, an oxidoreductase enzyme catalyzing the oxidation of said symmetrical sulfide to symmetrical sulfone; optionally at least one cofactor C of said enzyme E; and an oxidant, which allows in particular the implementation of said process.

The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors.

Methods and compositions for the oxidation of short alkanes by engineered microorganisms expressing enzymes are described, along with methods of use.

The instant disclosure is in the field of biosciences, more particularly towards molecular and industrial biotechnology. The present disclosure relates to recombinant methanotrophic bacteria capable of synthesizing indigo from methane, a method of developing said recombinant methanotrophic bacteria, and a method of indigo biosynthesis by the recombinant methanotrophic bacteria in presence of a methane source.

Disclosed are a construction method of a recombinant drug-resistant Mycobacterium bovis (M. bovis) Bacillus Calmette-Guerin (BCG) strain and a pharmaceutical composition for treating tuberculosis (TB). The construction method includes: using BCG as an original bacterial strain to construct a drug-resistant BCG strain resistant to at least one selected from the group consisting of STR, LFX, EMB, PRO, PAS, and AMK; and further inserting sequence fragments that can express related antigens Ag85b and Rv2628 causing an immune response into a genome of the strain to construct a recombinant drug-resistant BCG strain. The recombinant drug-resistant BCG strain can compete with Mycobacterium tuberculosis (Mtb) for growth, thereby accelerating the death of Mtb. When used in combination with a drug for treating TB, the recombinant drug-resistant BCG strain can further enhance a therapeutic effect for Mtb, and can also avoid re-infection of a patient.